Artelo Biosciences, Inc. — Form 10-Q Summary
Reporting period: Fiscal third quarter and nine months ended May 31, 2021; filed July 2021. Artelo is a clinical-stage biopharmaceutical company developing therapies targeting lipid-signaling pathways, including the endocannabinoid system. It had no product revenue.
Financial performance and liquidity
| Metric | Three months ended May 31, 2021 | Nine months ended May 31, 2021 | Prior comparable period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Operating expenses | $2.25 million | $5.55 million | $0.95 million and $3.66 million |
| Net loss | $2.25 million | $5.55 million | $0.95 million and $3.63 million |
| Net loss per share, basic and diluted | $0.10 | $0.33 | $0.27 and $1.06 |
| Cash used in operating activities | Not presented by quarter | $4.60 million | $3.47 million |
- Expense mix: Nine-month R&D was $2.22 million, professional fees $868,293, and general and administrative expense $2.46 million. No operating margin is meaningful because the company had no revenue.
- Balance sheet at May 31, 2021: Cash and cash equivalents were $10.05 million; current assets $10.30 million; current liabilities $423,943; working capital $9.88 million; total assets $12.34 million; and stockholders’ equity $11.92 million. No borrowings are reported.
- Cash flows, nine months: Financing provided $12.52 million, including $7.61 million from stock issuance and $6.02 million from warrant exercises, before issuance costs. Cash increased $7.91 million from August 31, 2020.
Changes versus prior period
- Quarterly operating expenses rose $1.30 million year over year, driven mainly by higher R&D and G&A costs, including payroll and director compensation and stock-based compensation.
- Nine-month operating expenses increased $1.90 million and net loss increased $1.92 million year over year. Management attributed higher R&D spending principally to the ART27.13 CAReS study and ART26.12 lead identification; higher professional fees included accounting/control work, intellectual-property legal costs, and transfer-agent costs.
- Cash rose from $2.14 million at August 31, 2020 to $10.05 million, primarily following the October 2020 public offering and warrant exercises. Common shares outstanding increased from 4.99 million at August 31, 2020 to 23.15 million at May 31, 2021.
Outlook, risks and notable items
- Going concern: The filing states that substantial doubt exists about Artelo’s ability to continue as a going concern. It has an accumulated deficit of $15.02 million, no established revenue source, and expects to need additional capital. Management said available resources may not fund operations for at least the next 12 months and gave no assurance that additional financing will be available.
- Development outlook: Artelo reported that the first patient in its Phase 1b/2a ART27.13 CAReS trial was dosed in April 2021. ART26.12 was in late-stage lead optimization; clinical studies in cancer were anticipated in the second half of 2022 or early 2023, subject to development progress and COVID-19 impacts. ART12.11, a CBD cocrystal, remained preclinical. These are forward-looking plans, not assured milestones.
- Risks: Clinical and regulatory uncertainty, trial recruitment and supply-chain delays, COVID-19 impacts, reliance on third-party research and manufacturing, controlled-substance regulation, intellectual-property and license risks, and the need for further financing. The company also highlights potential dilution from future equity financing.
- Financing after quarter-end: After May 31, 2021, Artelo issued 1,344,870 shares through its at-the-market program for net proceeds of $1.56 million.
- Other commitments: A related-party office lease commencing June 1, 2021 has a 39-month term, with payments of $32,918 within one year and $110,680 over the stated lease term. The company reported no material legal proceedings and no material off-balance-sheet arrangements.
Important facts for investors to verify
- Whether subsequent financing and spending provide adequate runway, given management’s going-concern warning and stated expectation that cash may not cover at least the next 12 months.
- Progress, enrollment, safety, and timing of the ART27.13 CAReS trial, and the evidence supporting ART26.12’s planned development timeline.
- Future operating cash burn and the extent to which increased expenses reflect clinical progress versus recurring overhead and stock-based compensation.
- Potential dilution from outstanding warrants and options, future ATM sales, or other capital raises; confirm share counts and warrant terms against subsequent filings.
- COVID-19, supply, regulatory, and licensing developments that could delay trials or increase development costs.